Clinical trial · no report yet · Phase 3
DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
- NCT04071457 ↗
- Active not recruiting
- SWOG Cancer Research Network
- 138 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 133 | |
| YouTube | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide; Daratumumab/rHuPH20
- Arms
- Study Entry / Screening · No intervention
- Arm 1: Lenalidomide · Active comparator
- Arm 2: Lenalidomide + Daratumumab/rHuPH20 · Experimental
- Arm 1a: Continue Lenalidomide · Active comparator
- Arm 1b: Stop Lenalidomide · No intervention
- Arm 2a: Continue Lenalidomide + Daratumumab/rHuPH20 · Active comparator
- Arm 2b: Stop Lenalidomide + Daratumumab/rHuPH20 · No intervention
- Enrollment
- 1,100 (estimated)
- Primary outcomes
- Overall Survival
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI), Janssen, LP
- Start
- Aug 13, 2019
- Primary completion
- Sep 2032 (estimated)
- Results posted
- No
- Registry record
- NCT04071457 · updated Sep 17, 2026
Publications
linked from the registry- Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):847-852. doi: 10.1016/j.clml.2022.07.011. Epub 2022 Jul 21. PubMed 35985959